Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meg Doherty

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
The Lancet. HIV|November 28, 2017
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling studyAndrew N Phillips, Valentina Cambiano, Fumiyo Nakagawa, et al.
The Lancet. Infectious Diseases|December 5, 2017
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysisRavindra K Gupta, John Gregson, Neil Parkin, et al.
The Lancet. Global Health|June 22, 2023
Description of the first global outbreak of mpox: an analysis of global surveillance dataHenry Laurenson-Schafer, Nikola Sklenovská, Ana Hoxha, et al.
The Lancet. HIV|July 23, 2024
IAPAC-Lancet HIV Commission on the future of urban HIV responsesJosé M Zuniga, Corey Prachniak, Nicoletta Policek, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
The Lancet. Global Health|August 9, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
The Lancet. Global Health|August 2, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
The Lancet. HIV|November 28, 2017
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling studyAndrew N Phillips, Valentina Cambiano, Fumiyo Nakagawa, et al.
The Lancet. Infectious Diseases|December 5, 2017
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysisRavindra K Gupta, John Gregson, Neil Parkin, et al.
The Lancet. Global Health|June 22, 2023
Description of the first global outbreak of mpox: an analysis of global surveillance dataHenry Laurenson-Schafer, Nikola Sklenovská, Ana Hoxha, et al.
The Lancet. HIV|July 23, 2024
IAPAC-Lancet HIV Commission on the future of urban HIV responsesJosé M Zuniga, Corey Prachniak, Nicoletta Policek, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
The Lancet. Global Health|August 9, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
The Lancet. Global Health|August 2, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
Pageof 12